The steroidal FXR agonist obeticholic acid is approved as a second-line treatment for patients with primary biliary cholangitis (PBC) and has also shown anti-fibrotic effects in NASH [10]. The gene discussed is NR1H4; the disease is primary biliary cholangitis.